NEW YORK (GenomeWeb News) — Stratos Biosystems said Monday that it has completed pilot production capability for a new protein chip technology that could be used in biomarker-discovery programs for early cancer detection.
Stratos said its EC-Affinity chips for MALDI mass spectrometry are designed to give researchers a high-throughput affinity chromatography tool that is based on a new “self-assembling surface chemistry.”
The biochip technology will be used to detect “extremely rare proteins,” Stratos said, and will address what it calls a “major problem of lack of capacity and functionality” in detecting cancer-related proteins.
The company said it is now actively seeking new collaborators and partners.
Stratos has been funded by numerous groups and individuals, including its chief scientist Mark Stolowitz. In 2001 Stolowitz left Bothell, Wash., protein chip technology company Prolinx, where he was chief technology officer, to become vice president of biochip technologies at Lumicyte.